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Objectives. Screening for type 2 diabetes has been
recommended and targeted screening might be an
efficient way to screen. The aim was to investigate
whether diabetic patients identified by a targeted
screening procedure differ from newly diagnosed
diabetic patients in general practice with regard to
the prevalence of macrovascular complications.
Design. Cross-sectional population-based study.
Setting. Population study, primary care.
Subjects. Diabetic patients identified by a population-
based targeted screening procedure (SDM patients),
consisting of a screening questionnaire and a fasting
capillary glucose measurement followed by diagnostic
testing, were compared with newly diagnosed diabetic
patients in general practice (GPDM patients).
Ischaemic heart disease and prior myocardial
infarction were assessed by ECG recording.
Peripheral arterial disease was assessed by the
ankle-arm index. Intima-media thickness of the
right common carotid artery was measured with
ultrasound.
Results. A total of 195 SDM patients and 60 GPDM
patients participated in the medical examination.
The prevalence of MI was 13.3% (95% CI 9.3–
18.8%) and 3.4% (1.0–11.7%) in SDM patients and
GPDM patients respectively. The prevalence of
ischaemic heart disease was 39.5% (95% CI 32.9–
46.5%) in SDM patients and 24.1% (15.0–36.5%) in
GPDM patients. The prevalence of peripheral arterial
disease was similar in both groups: 10.6% (95% CI
6.9–15.9%) and 10.2% (4.7–20.5%) respectively.
Mean intima-media thickness was 0.85 mm (±0.17)
in SDM patients and 0.90 mm (±0.20) in GPDM
patients. The difference in intima-media thickness
was not statistically significant.
Conclusions. Targeted screening identified patients
with a prevalence of macrovascular complications
similar to that of patients detected in general
practice, but with a lower degree of hyperglycaemia.
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epidemiology, macrovascular complications,
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Introduction
Type 2 diabetes is a common and serious disease.
People with type 2 diabetes have a two to fourfold
higher risk of cardiovascular mortality, compared
with people who do not have diabetes [1]. The fact
that this higher risk is already present in newly
diagnosed diabetic patients has been shown in
population-based studies [2, 3]. Several of these
studies have also shown that the prevalence of
macrovascular disease in newly diagnosed diabetic
patients is intermediate between the prevalence in
previously diagnosed diabetic patients and the
prevalence in individuals with normal glucose
tolerance [4–6]. The presence of diabetic complica-
tions at the time of clinical diagnosis is one of the
reasons why screening is recommended for type 2
diabetes [7]. Screening is directed at the identifica-
tion of diabetic patients at an early stage of the
disease, when there are few complications, if any.
Universal screening implies screening every person
in the entire population. The performance of an oral
glucose tolerance test (OGTT) or a fasting or random
glucose measurement in the entire study population,
as has been the case in population-based studies of
glucose intolerance, can be considered as universal
screening.
Targeted screening seems to be a more practical
and efficient way of screening. In this type of
screening a high-risk population is first selected by
a questionnaire or a risk score and the performance
of the ‘invasive’, and in case of an OGTT, time-
consuming, diagnostic test is restricted to this high-
risk population. However, targeted screening studies
to date have only focused on the yield of the
screening procedure, and none have yet described
the prevalence of macrovascular complications in
diabetic patients identified by targeted screening [8–
10]. In particular, it is unclear to what extent these
diabetic patients differ from newly diagnosed dia-
betic patients in general practice. With screening
one would expect to identify patients earlier and
with a lower prevalence of complications. In view of
these considerations, we compared the prevalence of
ECG abnormalities and peripheral arterial disease
and the mean carotid intima-media thickness in
diabetic patients detected by targeted screening and
newly diagnosed diabetic patients in general prac-
tice. This study was based on a population-based
targeted screening procedure that consisted of a
screening questionnaire [11] and a fasting capillary
whole blood glucose measurement followed by
diagnostic testing (OGTT) in high-risk individuals
[12].
Material and methods
Study population
Diabetic patients detected by targeted screening. The
targeted screening procedure was carried out from
1998 to 2000 in the West-Friesland region of the
Netherlands, amongst 11 679 inhabitants aged 50–
75 years, as described previously [12]. Briefly, the
first step of the screening procedure consisted of the
Symptom Risk Questionnaire (SRQ), which includes
questions about age, sex, body mass index (BMI),
family history of diabetes, use of antihypertensive
medication, frequent thirst, shortness of breath,
claudication, and use of a bicycle for transportation
[11]. The SRQ was developed in the Hoorn Study to
identify people at increased risk of having undiag-
nosed type 2 diabetes [11]. The SRQ was validated
against the 1999 WHO diagnostic criteria of diabe-
tes in a separate random sample of the population of
Hoorn. The sensitivity, specificity, positive and neg-
ative predictive value of an SRQ score of 6 are 66,
70, 13 and 97% respectively (A. M. W. Spijkerman,
unpublished data). Participants with an SRQ score
£6 were considered to be at low risk for undiagnosed
diabetes, and were therefore not invited to partici-
pate in any further testing. For individuals with an
SRQ score >6, the second step of the screening was a
fasting capillary whole blood glucose measurement.
In all individuals with a capillary whole blood glu-
cose level >5.5 and £8.5 mmol L)1, a venous sam-
ple was drawn on the same occasion, and a 75 g
OGTT was performed within 2 weeks. Participants
with a capillary whole blood glucose of >8.5 did not
have an OGTT because their fasting levels were
considered too high. Therefore, a fasting venous
sample was drawn on two different occasions and
diagnosis was based on two fasting plasma glucose
measurements. The 1999 WHO diagnostic criteria
for diabetes were applied: fasting plasma glucose of
‡7.0 mmol L)1 on two separate occasions, or a 2-h
plasma glucose level of ‡11.1 mmol L)1 [13]. The
total response for the invitation to the screening was
78% and the SRQ was calculated for 7736 par-
ticipants, after exclusion of 741 nonparticipants,
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417 previously diagnosed diabetic patients and 275
people with missing data or missing informed con-
sent. A total of 3301 participants had an SRQ >6
and the response rates for the capillary blood glucose
measurement and OGTT were 87 and 89%
respectively. Amongst the participants of the OGGT,
216 had impaired glucose metabolism. The non-
participants of the SRQ were significantly younger
than participants and more likely to be men. The
nonresponders for the OGTT were older than people
who did participate. In total, 217 previously undi-
agnosed diabetic patients were identified in the tar-
geted screening [12].
Diabetic patients newly diagnosed in general prac-
tice. All diabetic patients, aged 50–75 years, who
were newly diagnosed from 1999 to 2001 in gen-
eral practice in the towns of Den Helder and Me-
demblik (situated to the north of the West-Friesland
region) were invited to participate in the study. For
people without symptoms of hyperglycaemia,
a fasting capillary glucose measurement of
‡6.1 mmol L)1 or fasting plasma glucose of
‡7.0 mmol L)1 on two separate occasions were the
criteria for a diagnosis of diabetes. For individuals
with symptoms of hyperglycaemia, (thirst, fatigue,
frequent urination), one fasting capillary glucose
measurement of ‡6.1 mmol L)1 or one fasting
plasma glucose of ‡7.0 mmol L)1 was sufficient for
a diagnosis of diabetes, according to the guidelines of
the Dutch College of General Practice [14]. These
diagnostic cut-off points are in accordance with the
1999 WHO diagnostic fasting criteria for diabetes.
The general practitioners identified a total of 81
newly diagnosed diabetic patients. Of these, 10 were
too young to participate in the present study
(<50 years). As a result, 71 newly diagnosed dia-
betic patients were eligible and were invited con-
secutively to participate in the study. Ascertainment
of referral of all newly diagnosed diabetic patients
was not possible, because of Dutch privacy legisla-
tion.
Individuals with screening-detected type 2 diabe-
tes (SDM) and all newly diagnosed diabetic patients
in general practice (GPDM) were invited to undergo
an extensive medical examination, including assess-
ment of macrovascular complications.
Screening, diagnostic tests and physical examina-
tion were carried out in a standardized manner by
trained PhD students and research assistants at the
Diabetes Research Center in Hoorn. All participants
gave written informed consent. The Ethics Commit-
tee of the VU University Medical Center approved the
study.
Measurements. Capillary fasting whole blood glucose
levels were obtained with a Hemocue Blood Glucose
Analyzer, based on the glucose-dehydrogenase
method (Hemocue Nederland, Oisterwijk, the Neth-
erlands). Plasma glucose concentrations were as-
sessed by means of a glucose hexokinase method
(Roche Diagnostics GmbH, Mannheim, Germany).
HbA1c was determined by ion-exchange high-per-
formance liquid chromatography with a Modular
Diabetes Monitoring System (Bio-Rad, Veenendaal,
the Netherlands). Serum total cholesterol, HDL
cholesterol and triglycerides were measured by
means of enzymatic techniques (Boehringer-Mann-
heim, Mannheim, Germany). The Friedewald for-
mula was used to calculate LDL cholesterol, except if
the triglyceride level was >4.5 mmol L)1, then LDL
cholesterol was considered missing (n ¼ 5 amongst
SDM, n ¼ 1 GPDM). High cholesterol was defined as
serum total cholesterol ‡5.0 mmol L)1, and high
LDL cholesterol was defined as LDL-cholesterol
‡3.0 mmol L)1. Dyslipidaemia was considered pre-
sent when HDL cholesterol was £1.0 mmol L)1 in
men or £1.1 in women and triglyceride was
‡2.0 mmol L)1 [15]. The albumin-to-creatinine ra-
tio (ACR) was calculated to determine the presence of
microalbuminuria. Urinary albumin was measured
by means of rate nephelometry (Array Protein Sys-
tem, Beckman, Galway, Ireland). Urinary creatinine
was measured by means of a modified Jaffe´ method.
Subjects were classified as having (micro)albumin-
uria if they had an ACR of >2.0 mg mmol)1 [16].
Information about smoking habits and medication
use was assessed by means of a questionnaire.
Weight, height, and hip and waist circumferences
were measured with subjects barefoot, wearing light
clothes only. Blood pressure was calculated as the
mean of two measurements, performed in a sitting
position after 5 min of rest, with a random-zero
sphygmomanometer (Hawksley-Gelman, Lancing,
Sussex, UK). Overweight was defined as BMI
‡25 kg m)2. Individuals were considered to be
hypertensive if they had a diastolic blood pressure
‡90 mmHg, and/or a systolic blood pressure
‡140 mmHg, and/or they were taking antihyper-
tensive medication [17].
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Macrovascular complications. Standard 12-lead ECGs
were recorded (CardioControl, Delft, The Nether-
lands) and coded according to the Minnesota code
with an automated diagnostic classification sys-
tem [Modular ECG Analysis System (MEANS)]
[18, 19]. Prior myocardial infarction was defined as
the presence of Minnesota codes 1-1 or 1-2 on the
ECG-recording. Ischaemic heart disease was consid-
ered to be present with Minnesota codes 1-1, 1-2,
1-3, 4-1, 4-2, 4-3, 5-1, 5-2, 5-3 or 7-1 on the ECG-
recording.
Doppler-assisted systolic blood pressure measure-
ments were made in duplicate from the brachial,
posterior tibial and dorsalis pedis arteries on both
sides. The average pressure was calculated for the
posterior tibial and dorsalis pedis arteries in each leg.
The highest of these average pressure levels was
used to calculate the ankle-arm index for each leg.
Peripheral artery disease was defined as the presence
of ankle-arm index <0.90 in either leg. An ankle-
arm index of >1.50 (which possibly reflects medial
arterial calcification [20] was not observed in any of
the participants.
Intima-media thickness of the right common
carotid artery was obtained with the use of an
ultrasound scanner equipped with a 7.5 MHz linear
array probe (Pie 350 Series; Pie Medical BV,
Maastricht, The Netherlands). The ultrasound
scanner was connected to a personal computer
equipped with vessel wall movement detection
software and an acquisition system (Wall Track
System 2; Pie Medical BV). This integrated set-up
makes it possible to measure intima-media thick-
ness, as described in detail elsewhere [21, 22].
Briefly, the carotid artery was visualized in B-mode,
and an M-line perpendicular to the artery was
positioned 10 mm proximal to the carotid bulb.
After switching to M-mode, data acquisition in a
real-time A-mode presentation on the computer
screen was possible after trackball-assisted identifi-
cation of the lumen of the artery. Ultrasound data
were obtained during three consecutive measure-
ments, each consisting of a 4-s period, triggered by
the R-top of a simultaneously recorded ECG.
Intima-media thickness of the posterior carotid
wall was defined as the distance from the leading
edge interface between lumen and intima to the
leading edge interface between media and advent-
itia, automatically calculated from digitized cumu-
lative radio frequency signals. The mean
intima-media thickness of the three measurements
was used in the analyses.
Statistical analyses
The characteristics of SDM and GPDM patients were
stratified for sex because of the well-known differ-
ence in cardiovascular risk factors between men and
women. The characteristics of SDM and GPDM
patients were compared, using Student’s t-test for
continuous variables, the chi-square test for dichot-
omous variables and the Mann–Whitney U-test for
skewed variables. Fasting plasma glucose, HbA1c
and triglyceride were presented as median and
interquartile range because of their skewed distri-
bution. Confidence intervals were calculated with
confidence interval analysis software, version 2.0
[23]. P-values were based on two-sided tests, and
considered to be statistically significant if less than
0.05.
Results
In total, 195 of the 217 screening-detected diabetic
patients participated in the assessment of macrovas-
cular complications. The general practitioners iden-
tified a total of 71 newly diagnosed diabetic patients.
Of these, eight declined participation in the study
and three did not participate in the assessment of
macrovascular complications. As a result, a total of
195 SDM and 60 GPDM patients underwent the
extensive physical examination. Nonparticipants in
the medical examination tended to be older in both
groups, but this difference was not statistically
significant. There were no differences between
participants and nonparticipants in the physical
examination in either group with respect to sex and
glucose levels (data not shown). In the SDM group,
data were complete for 195, 180 and 165 patients
for ECGs, peripheral arterial disease and intima-
media thickness respectively. In the GPDM group,
two ECGs were missing, data on peripheral arterial
disease were complete for 59 patients and intima-
media thickness measurements were obtained from
51 patients. Patients with missing intima-media
thickness data were more obese in both groups.
Table 1 shows the baseline characteristics of
diabetic patients identified by screening and in
general practice, stratified according to sex. The
SDM patients were older than the GPDM patients,
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reaching statistical significance only in women.
Glucose and HbA1c were higher in GPDM patients
than in SDM patients, but the difference in glucose
was not statistically significant in women. HDL
cholesterol was significantly lower in the GPDM
women, but the prevalence of lipid abnormalities
was similar in both groups and both sexes. In
women, the prevalence of obesity was similar in
Table 1 Baseline characteristics of diabetic patients identified by targeted screening and in general practice stratified according to sex
Women Men
SDM (n ¼ 94) GPDM (n ¼ 30) SDM (n ¼ 101) GPDM (n ¼ 30)
Age (years) 65.3 (6.1) 62.3 (7.4)* 61.5 (7.4) 60.4 (6.7)
Fasting plasma glucose (mmol L)1) 7.9 (7.3–8.9) 8.7 (7.7–9.8) 7.8 (7.3–9.1) 9.3 (7.5–12.2)*
HbA1c (%) 6.4 (5.8–7.1) 8.1 (7.4–11.3)* 6.3 (5.7–7.1) 8.7 (7.4–10.7)*
Cholesterol (mmol L)1) 5.9 (1.1) 5.7 (0.9) 5.5 (1.1) 5.3 (1.1)
High cholesterol (%) 79.8 79.3 66.7 53.3
LDL cholesterol (mmol L)1) 3.64 (0.94) 3.56 (0.88) 3.50 (0.98) 3.44 (1.05)
High LDL cholesterol (%) 81.7 75.9 72.9 62.1
HDL cholesterol (mmol L)1) 1.4 (0.4) 1.2 (0.3)* 1.1 (0.2) 1.1 (0.4)
Triglycerides (mmol L)1) 1.7 (1.2–2.4) 1.9 (1.7–2.6) 1.7 (1.2–2.4) 1.6 (1.3–2.1)
Dyslipidaemia (%) 18.1 20.7 23.2 23.3
Lipid-lowering medication (%) 18.1 16.7 21.8 16.7
BMI (kg m)2) 30.1 (6.2) 31.1 (6.3) 29.5 (4.4) 27.6 (4.6)*
Overweight (%) 85.1 86.7 92.1 62.1*
Waist–hip ratio 0.92 (0.08) 0.92 (0.07) 1.01 (0.06) 1.00 (0.07)
Systolic blood pressure (mmHg) 143 (20) 140 (25) 140 (16) 143 (21)
Diastolic blood pressure (mmHg) 86 (10) 82 (12) 85 (9) 85 (11)
Hypertension (%) 80.9 70.0 70.3 46.7*
Antihypertensive medication (%) 56.4 56.7 37.6 23.3
Microalbuminuria (%) 17.2 23.3 17.2 30.0
Current smoking (%) 11.7 26.7* 18.8 36.7*
Data are presented as mean (SD), median (interquartile range, IQR) or percentages. SDM screening detected diabetes mellitus,
GPDM diabetes mellitus newly diagnosed in general practice. High cholesterol was defined as serum total cholesterol ‡5.0 mmol L)1 and
high LDL cholesterol as LDL cholesterol ‡3.0 mmol L)1. Dyslipidaemia was considered present when HDL cholesterol was £1.0 mmol L)1
in men or £1.1 in women and trigyceride was ‡2.0 mmol L)1. BMI, body mass index, overweight was defined as BMI ‡25. Hypertension
was defined as diastolic blood pressure ‡90 mmHg, systolic blood pressure ‡140 mmHg, or use of antihypertensive medication, micro-
albuminuria as an albumin-to-creatinine ratio >2.0. *Significantly different from SDM (P < 0.05).
Table 2 Prevalence of macrovas-
cular complications at the time of
diagnosis in diabetic patients iden-
tified by targeted screening and in
general practice
SDM GPDM
All participants
Myocardial infarction (%) 13.3 (9.3–18.8) 3.4 (1.0–11.7)*
Ischaemic heart disease (%) 39.5 (32.9–46.5) 24.1 (15.0–36.5)*
Peripheral arterial disease (%) 10.6 (6.9–15.9) 10.2 (4.7–20.5)
Intima-media thickness (mm) 0.85 (0.17) 0.90 (0.20)
Women
Myocardial infarction (%) 13.8 (8.3–22.2) 3.4 (0.6–17.2)
Ischaemic heart disease (%) 46.8 (37.0–56.8) 24.1 (12.2–42.1)*
Peripheral arterial disease (%) 8.1 (4.0–15.9) 6.7 (1.8–21.3)
Intima-media thickness (mm) 0.86 (0.14) 0.83 (0.18)
Men
Myocardial infarction (%) 12.9 (7.7–20.8) 3.4 (0.6–17.2)
Ischaemic heart disease (%) 32.7 (24.3–42.3) 24.1 (12.2–42.1)
Peripheral arterial disease (%) 12.8 (7.5–21.0) 13.8 (5.6–30.6)
Intima-media thickness (mm) 0.85 (0.19) 0.97 (0.20)*
Data are presented as percentages (95% CI) or mean (SD). SDM, screening-detected diabetes
mellitus; GPDM, diabetes mellitus newly diagnosed in general practice. *Significantly different from
SDM (P < 0.05).
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both groups, but GPDM men were significantly less
likely to be overweight than SDM men. Microalbu-
minuria was more prevalent in GPDM men and
women, although the difference was not statistically
significant. GPDM men and women were more likely
to smoke than SDM patients of either sex.
Table 2 shows the prevalence of macrovascular
complications at the time of diagnosis in diabetic
patients identified by screening and in general
practice. Prior myocardial infarction and ischaemic
heart disease were more frequently found in SDM
patients than in GPDM patients, and the difference
in ischaemic heart disease was statistically signifi-
cant in women. The prevalence of peripheral arterial
disease was slightly higher in SDM women than in
GPDM women. No difference in the prevalence of
peripheral arterial disease was observed between
SDM and GPDM men. Mean intima-media thickness
was significantly greater in GPDM men than in SDM
men.
Discussion
Screening for type 2 diabetes is directed at the
identification of patients at an early stage of the
disease. Consequently, with screening one would
expect to identify patients earlier in the development
of hyperglycaemia than when they are newly
diagnosed in general practice. Accordingly, diabe-
tes-related complications are also expected to be less
prevalent or less extensive in patients identified by
screening. In this study, the only difference in
macrovascular complications in the expected direc-
tion was the difference in intima-media thickness
(lower in SDM than in GPDM patients), and signi-
ficantly lower in men. The prevalence of peripheral
arterial disease was similar in both groups of
patients, whilst the prevalence of ischaemic heart
disease and previous myocardial infarction was even
higher in SDM patients. Although glucose and
HbA1c levels were lower in SDM compared with
GPDM patients, which might be an indication that
SDM patients were identified earlier in the develop-
ment of hyperglycaemia, other cardiovascular risk
factors such as hypertension were more frequently
present in SDM patients. This might be explained by
the targeted screening approach. The screening
questionnaire (SRQ) includes some cardiovascular
items such as use of antihypertensive medication,
shortness of breath and claudication. Consequently,
the SDM patients identified through targeted screen-
ing with the SRQ may be expected to have an
unfavourable cardiovascular risk.
The difference in diagnostic procedure between
SDM and GPDM patients might also contribute to
the differences in the prevalence of macrovascular
complications. In the SDM group, the diagnosis was
based on elevated fasting and 2-h plasma glucose
values whilst in the GPDM group it was based on
elevated fasting plasma glucose values only. The
diagnostic fasting glucose criteria for diabetes have
been shown to be less predictive of cardiovascular
disease [24] and mortality [3]. To investigate whe-
ther the difference in diagnostic procedure played a
role in our findings, we compared the prevalence of
myocardial infarction and ischaemic heart disease
between GPDM patients and those SDM patients
whose diagnosis was also based on fasting glucose
values (thus excluding 36 SDM patients). The
differences in the prevalence of myocardial infarc-
tion and ischaemic heart disease were similar to
those observed for the entire SDM group (data not
shown). Consequently, the difference in diagnostic
procedure is unlikely to provide an explanation for
our findings. Coverage of care has not influenced the
study results because in the Netherlands everyone is
insured for health care.
The low prevalence of previous myocardial infarc-
tion relative to the high intima-media thickness in
the GPDM group is not in line with the reported
positive association of intima-media thickness with
coronary heart disease [25, 26]. A healthy survivor
effect might have been present in the GPDM group,
indicating that all those who had high intima-media
thickness and myocardial infarction had already
died, even before the start of the study. Other
observations in our study, such as the difference
between sexes in intima-media thickness and the
positive associations with age and blood pressure
(data not shown), were similar to those reported in
the literature [26–29]. The low prevalence of
myocardial infarction in the GPDM group might
also indicate that diabetic patients who were newly
diagnosed as a consequence of a recent myocardial
infarction might not have been recruited for the
study, although GPs were encouraged to recruit all
newly diagnosed diabetic patients. The small sample
size of the SDM and GPDM groups, the small number
of patients with complications, and the resulting
imprecision, might provide an additional explan-
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ation for our findings. If the number of GPDM
patients had been higher, the difference in intima-
media thickness might have become statistically
significant (men and women together). However,
the similarity in prevalence of peripheral arterial
disease and the difference in prevalence of myocar-
dial infarction between the two groups might not
have been easily affected by a higher number of
GPDM patients.
Targeted screening implies the selection of a
high-risk population for diagnostic testing. Com-
pared with universal screening for type 2 diabetes,
targeted screening might miss individuals who do
have diabetes but do not have the risk factors
included in the first noninvasive screening test,
i.e. the young, less obese diabetic patients without a
family history of diabetes and/or without cardio-
vascular symptoms. One might speculate that these
missed patients may also have a lower prevalence
of macrovascular complications. Most noninvasive
screening tests for type 2 diabetes that can be used
in targeted screening to select a high-risk popula-
tion include obesity and at least one cardiovascular
item (most frequently hypertension) [30–33]. Thus,
the high-risk population identified by targeted
screening is at risk of both diabetes and cardiovas-
cular disease. This is illustrated by our previous
finding that a positive result on the Cambridge Risk
Score [31], a noninvasive screening test for type 2
diabetes, was associated with an increased mor-
tality risk [34], independent of the presence of
diabetes. Because of the identification of a popula-
tion at high risk of both diabetes and of cardiovas-
cular disease, targeted screening for type 2 diabetes
might be an efficient alternative to a screening
procedure that is restricted to hyperglycaemia
alone. Future studies need to determine the cost-
effectiveness of targeted screening strategies for
type 2 diabetes.
In conclusion, targeted screening for type 2
diabetes identified diabetic patients with a preval-
ence of macrovascular complications similar to that
found amongst newly diagnosed diabetic patients in
general practice, but with a lower degree of hyper-
glycaemia. Our study is the first confirmation of the
idea that targeted screening might be an efficient
way to identify people at high risk of undiagnosed
type 2 diabetes and of cardiovascular disease.
However, results from studies that address the
(cost)-effectiveness of early treatment following
detection by targeted screening need to be awaited
before targeted screening can be recommended.
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